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A B S T R A C T
The aim of this study was to evaluate the possible association between polymorphisms in the Vitamin D receptor gene
(VDR gene) and tendency for development of psoriasis vulgaris and diabetes mellitus in the population of Slavonia,
which is a region in the Eastern Croatia. In order to conduct the mentioned evaluation the restriction fragment length
polymorphisms (ApaI, BsmI and TaqI) in the Vitamin D receptor gene were researched in three groups of patients: pa-
tients suffering only from psoriasis vulgaris, patients suffering only from diabetes mellitus, and patients suffering at the
same time from both diseases. Four most common genotypes were found in all standardized control patients: triple het-
erozygotes BbAaTt (in 29.3% of the studied patients), bbAaTT (in 18.6% of the studied patients), bbaaTT (in 12.9% of the
studied patients) and BbAATt (in 8.6% of the studied patients). Three most common VDR 3’-RFLP haplotypes deter-
mined in this study were: three-component baT, Bat and bAT haplotype. Results of the Hardy-Weinberg equilibrium
showed presence of BsmI polymorphism genotype frequencies disequilibrium in the group of patients suffering from pso-
riasis and ApaI polymorphism in the group of patients suffering from both diseases. According to the same statistical test
all conditions for TaqI polymorphism genotype frequency were fulfilled in all groups of studied patients. There was no
significant difference in distribution of BsmI, ApaI or TaqI polymorphism genotype frequencies between control patients
and any of the subgroup of studied patients. In studied population none of analysed polymorphisms individually was as-
sociated with the risk of development of psoriasis, diabetes or combined phenotype.
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Introduction
Psoriasis and diabetes represent serious public health
problems. Psoriasis is a chronic immune-inflammatory-
-mediated skin disease that affects up to 3.0% population
worldwide1. Diabetes mellitus is a chronic disease caused
by the inability of pancreatic beta cells to maintain ade-
quate insulin secretion to prevent hyperglycemia. Ac-
cording to the International Diabetes Federation global
prevalence of disease is 6.6%2. They have negative influ-
ence on the quality of life of affected patients due to the
fact that both diseases are chronic and because of later
complications (psoriatic arthritis, diabetic neuropathy,
nephropathy, retinopathy and micro-angiopathy)3–5. As-
sociation between psoriasis and diabetes was discovered
several decades ago. In 1897, Strauss drew particular at-
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tention to development of diabetes mellitus in patients
with psoriasis6. Since then, many authors studied patho-
logical values of blood sugar (GUK) in patients with pso-
riasis vulgaris7,8 as well as statistical correlation between
psoriasis and diabetes9–14. The prevalence of psoriasis
and diabetes in Eastern Croatia is significant and more
and more often one patient is suffering from both dis-
eases. The prevalence of psoriasis and diabetes mellitus
in this part of Croatia is 1.6% and 6.7%, respectively15,16.
There are data showing genetic background in etiology of
psoriasis and diabetes. Some authors consider that one of
the causes for development of both psoriasis and diabetes
could be polymorphism in the vitamin D receptor gene17,18.
Vitamin D receptor (VDR) belongs to the group of ste-
roid and thyroid hormone receptors, the family of activa-
tion transcription factors and the super family of the
core’s hormone receptors that include thyroid, steroid
and retinoid receptors19–21. It has been found in high con-
centration in T lymphocytes and in macrophages popula-
tion. The maximal concentration was found in immature
immune thymus cells and in mature CD-8 T lymphocy-
tes19,20. In the skin VDR was found in keratinocytes22,
Langerhan’s cells23, monocytes24, fibroblasts25, endothe-
lial cells26 and in activated T lymphocytes27. Presence of
VDR in most of the immune system cells, especially in
dendritic cells, as well as in CD8+ lymphocytes, CD4+
lymphocytes28 and in monocytes/macrophages29, further
emphasizes its immunoregulatory effect20,30. In respect
to that, the role of Vitamin D in autoimmune diseases is
being researched, especially in therapeutic sense31. The
authors have been researching correlation between dia-
betes mellitus, as an autoimmune disease, and Vitamin D
for years. De Luca and associates concluded that 1,25-Di-
hydroxiviatmin D3 can prevent and suppress experimen-
tal autoimmune encephalomyelitis, rheumatoid arthri-
tis, systemic lupus, and type I diabetes. The authors
explained it by claiming that Vitamin D has a suppres-
sive effect on inflammatory T cells. Therewith Vitamin D
could have important role in new therapeutic approaches
to autoimmune diseases31. Casteels and associates sug-
gest that 1,25(OH)2D3 could have protective role against
onset of diabetes as a result of increased apoptosis of the
Th1 autoimmune effector32. Also, Mathieu and associ-
ates confirmed in their study that long-term therapy
with high dosage of 1,25(OH)2D3 can decrease insulinitis
incidence in spontaneous autoimmune diabetes without
significant side effects33. The gene encoding VDR was lo-
cated on chromosome 12, region 12q13.11 and it is cover-
ing 62 359 base pairs (bp). Its length is 75 kb of the
genomic DNA, it is composed of eight encoding exons
(II-IX), six non-coding exons (Ia to If), several promoting
regions and 3`-UTR poki A tract. The difference between
exons and introns is that exons are codes of proteins,
while introns are not involved with the coding for pro-
teins. The intron sequences were once considered to be
junk DNA, however, people have recently realized that
some of them may be functional. These DNAs may har-
bor a variety of elements that regulate transcription, e.g.,
untranslated RNAs and splicing control elements34. Ex-
ons II to IX form structural part of the VDR gene. hVDR
promoters were found in exons If, Ia and Id. That region
is responsible for different connections during transcrip-
tion, resulting in occurrence of three types of hVDR
mRNA, through which VDR protein is going to be tran-
slated20,35. Specificity of the VDR gene in comparison to
other core receptor genes lies in the presence of exon 5.
Several allelic versions of the VDR gene were identified.
Polymorphisms in VDR gene were mostly researched by
three restriction enzymes: Apal, BsmI and TaqI19,20.
By several occasions scientists were examining cer-
tain variants of alleles and haplotypes as markers for
possible development of osteoporosis and metabolic bone
disorders with higher fracture risk. Special attention was
given to the possible role of VDR gene variants in devel-
opment of breast cancer, prostate gland cancer, osteo-
arthritis, artery arteriosclerosis, diabetes mellitus, hyper-
parathyroidism, certain infective diseases and psoriasis19.
There are several polymorphisms in hVDR gene, whe-
reat there are significant differences in studied VDR
polymorphisms between different races or ethnic groups.
The objective of many studies was to research associa-
tions between different VDR genotypes (AA, Aa, aa, BB,
Bb, bb, TT, Tt, tt) and tendency for development of cer-
tain autoimmune diseases, such as Addison’s disease, au-
toimmune hepatitis, Grave’s disease36–38.
The objective of this study was to research gene vari-
ants, that is, restriction fragment length polymorphisms
(ApaI, BsmI and TaqI) in the Vitamin D receptor gene in
patients suffering only from psoriasis vulgaris, patients
suffering only from diabetes mellitus and patients suffer-
ing at the same time from both diseases, as well as possi-
ble association between polymorphisms in VDR gene
(VDR gene) and tendency for development of psoriasis




The study was performed in 2007. It included 100
randomly selected patients in the region of Eastern Croa-
tia: 35 patients suffering both from psoriasis and diabe-
tes, 40 patients suffering from psoriasis but not from dia-
betes and 25 patients suffering from diabetes but not
from psoriasis. All patients were diagnosed at the Clinic
for Internal Medicine and at the Department for Derma-
tology at the Clinical Hospital Centre Osijek in Osijek, in
accordance with existing criteria for diagnosing psoriasis
and diabetes in Croatia and worldwide. The mean age of
all patients included in the study was 54.6±16.1 (the
range was from 10 to 80 years of age). 46 of them were
women and 54 were men. Diagnosing criteria for psoria-
sis was pathohistological diagnostics. All patients were
examined by dermatologists/venereologists and endocri-
nologists, blood samples were collected from the patients
and blood glucose level was measured. Also, detailed pso-
riasis and diabetes anamnesis was obtained. All data
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were entered into the questionnaires prepared for this
study only. During study no difference was made be-
tween patients suffering from diabetes Type I or Type II
and psoriasis – all patients were studied together. The
group of healthy control patients included 40 volunteers,
who had no family connections. They were also coming
form the region of Eastern Croatia, the mean age was
39.8±13.8 (the range was from 22 to 70 years of age). 20
of them were female and 20 were male. None of them had
clinical signs or family history of psoriasis and/or diabe-
tes mellitus. The study was approved by the Ethic Com-
mittee of the Clinical Hospital Centre Osijek and it has
been performed in accordance with its instructions. A
blood sample (5 mL) was collected from each patient,
both psoriatic and diabetic, as well as from healthy con-
trol patients. Genotype analysis was made in the Clinical
Institute for Nuclear Medicine and Radiation Prevention
at the Clinical Hospital Centre Osijek. The blood samples
were encoded and after the study was finished they were
destroyed.
Methods
High Pure Template Preparation kit, Light Cycler
FastStart DNA Master SYBR Green I Kit, DNA Molecu-
lar Weight Marker VIII were purchased from Roche Di-
agnostics, Mannheim, Germany.
¿ Primer 1 (5'-GGGAGACGTAGCAAAGG-3'),
¿ Primer 2 (5'-AGAGGTCAAGGGTCACTG-3'),
¿ Primer 3 (5'-CAGAGCATGGACAGGGAGCAAG-3') and
¿ Primer 4 (5'-GCAACTCCTCATGGCTGAGGTCTCA-3')
were purchased from Invitrogen (Paisley, UK)
Restriction enzymes BsmI, TaqI and ApaI are prod-
ucts of Sigma (Taufkirchen, Germany).
Genotyping
The genome DNA was extracted from 200 mL EDTA
blood using the isolation kit according to the producer’s
instructions.
Every DNA sample underwent 40 cycles of PCR on
the LightCycler machine (Roche Diagnostics, Mannheim,
Germany). Quality of PCR products was verified by melt-
ing curve analysis. Restriction fragment length polymor-
phisms were encoded as Bb (BsmI), Aa (ApaI) and Tt
(TaqI), where a capital letter means absence of the re-
striction site and a small letter means presence of the re-
striction site.
The BsmI restriction site (rs1544410) was detected by
amplifying the region that was overcoming the site with
one primer in exon 7 (Primer 1) and with second primer
in intron 8 of the VDR gene (Primer 2). The amplifica-
tion started with an initial denaturation step at 95°C,
then 5 seconds at 51°C and 15 seconds at 72°C. The
length of PCR products was 359 base pairs (bp). After the
amplification, the PCR products were digested with 5
units of the BsmI restriction enzymes for 2 hours at 65°C.
Then agarose gel (3%) electrophoresis with ethidium
bromide was performed. The bands were visualized un-
der UV-transilluminator (Pharmacia Biotech, Uppsala,
Sweden). Presence of the BsmI restriction site on both
alleles (determined as bb) resulted in 182 and 177 bp
fragments, whereas absence (BB) resulted in one non-di-
gested 359 bp fragment.
VDR gene region containing ApaI (rs 7975232) and
TaqI (rs 731236) restriction sites was obtained during
PCR reaction by using Primer 3 located in intron 8 and
primer 4 located in exon 9 of the VDR gene. The amplifi-
cation started with an initial denaturation step at 95°C
for 10 minutes, followed by 40 amplifying cycles at 95°C
for 10 seconds, then 5 seconds at 69°C and 30 seconds at
72°C – the length of PCR products was 740 bp. In order to
detect ApaI and TaqI restriction sites, every PCR prod-
uct was digested with 3 units for 2 hours at 65°C and
with 10 units of the ApaI enzyme for 2 hours at 65°C. Af-
ter digestion with ApaI, genotypes were identified as AA
(one non-digested PCR fragment of 740 bp), aa (two frag-
ments of 515 and 225 bp) and heterozygote Aa, depend-
ing on the presence or absence of a restriction site. TaqI
digestion revealed one obligatory restriction site, homo-
zygote TT (absence of the specific TaqI restriction site)
providing fragments of 490 bp and 245 bp. Homozygote tt
provides fragments of 290, 245 and 205 bp and heterozy-
gote Tt provides fragments of 490, 290, 245 and 205 bp.
Statistics
Departures from Hardy-Weinberg equilibrium were
assessed by using a permutation version of the Guo-
-Thompson exact test (10000 replications)39. Pairwise
linkage disequilibrium was assessed by two measures,
Lewontin’s |D’| and r2 coefficients40 (Haploview 4.0RC2
package, http://www.broad.mit.edu/mpg/haploview)41. For
continuous, unpaired data, Kruskall-Wallis and Mann-
-Whitney U-test were used.
For estimates of strength of association, odds ratios
and 95% confidence intervals were calculated using exact
logistic regression models from StatXact/LogXact-7 soft-
ware (Cytel Inc, Cambridge, MA, USA)42.
To correct for multiple testing, the Westfall-Young
max(T) permutation procedure43 (10000 randomizati-
ons), which accounts for the dependence structure be-
tween RFLPs, phenotypes and models. was applied (co-
-dominant model, PLINK version 0.99r, http://pngu.mgh.
harvard.edu/purcell/plink)44.
Haplotype patterns were estimated by Stephens-Don-
nelly coalescent-based Bayesian method45,46 (PHASE 2.1,
www.stat.washington.edu/stephens) and haplotype fre-
quency distributions compared by permutation testing
(10000 replicates). To maximize statistical power, only
common observed haplotypes (>10% in pooled samples)
were analyzed.
Permutation-corrected p-values <0.05 were taken as
significant.
Power calculations were performed using the Genetic
Power Calculator program (http://pngu.mgh.harvard.edu/
~purcell/gpc)47. A multiplicative model, two-tailed type I
error rate a=0.05 and a population disease prevalence of
0.02 (PV) and 0.06 (DM) were assumed.
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Results
Genotyping showed that four most common geno-
types (61% of all detected combinations) in studied pa-
tients in the region of Eastern Croatia were as follows (by
descending order): triple heterozygote genotype BbAaTt
(29.3%, 41 out of 140 patients), genotype bbAaTT (18.6%,
26 out of 140 patients), genotype bbaaTT (12.9%, 18 out
of 140 patients) and genotype BbAATt (8.6%, 12 out of all
140 standardized patients) (Table 1).
Tri-component baT, Bat and bAT haplotypes are three
most common VDR 3’-RFLP haplotypes in the studied
population (Table2).
Conditions of the Hardy-Weinberg equilibrium fulfil
TaqI polymorphism genotype frequencies in all patient
groups, as well as all polymorphisms in the combined
sample of all patients and in the control patients sample
(Table 3).
Hardy-Weinberg disequilibrium of BsmI genotype fre-
quencies (PV), i.e., ApaI polymorphism (DM+PV), were
found in patients with PV (psoriasis vulgaris), as well as
in the subgroup of patients with DM+PV (diabetes melli-
tus + psoriasis vulgaris).
Strong linkage disequilibria were observed for all
markers based on the calculation of |D’| (BsmI-ApaI
0.826|D’|1 ApaI-TaqI) and r2 coefficients (BsmI-ApaI
0.372r20.441 ApaI-TaqI, p<10–37, c2-test, df=1, n=100).
Under the presumption of permutation allele effects
model, no significant differences in distribution of geno-
type frequencies, as well as of allele frequencies of the
BsmI, ApaI or TaqI polymorphisms were found between
control patients and any of patient subgroups (PV, DM,
PV+DM).
There were no significant differences in allele-specific
risks, as well as no new significant associations between
tested phenotypes.
We had >80% power to detect allelic ORs of 0.3
(3.33), 0.37 (2.65) and 0.41 (2.45) corresponding to
the minor allele frequencies of 10, 20 and 30% (PV arm of
the study), i.e., 0.29 (3.4), 0.36 (2.8) and 0.38 (2.65)
for the DM arm of the study.
Discussion and Conclusion
This study showed that there were no significant dif-
ferences in allele-specific risks, as well as no new signifi-
cant associations between tested phenotypes. 15 out of
27 theoretic possible combinations of BsmI, ApaI and
TaqI genotypes in block 3’-B1 of the VDR gene were
found48. According to the available literature there were
several researchers who studied VDR locus as candidate
gene likely to cause development of diabetes mellitus
Type I or Type II. McDermott and associates studied
VDR gene and etiology of diabetes mellitus Type I in 93
families from South India. They analysed three VDR
polymorphisms using restriction enzymes TaqI, ApaI
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TABLE 1
DISTRIBUTION OF COMBINED ABSOLUTE GENOTYPE
FREQUENCIES OF THE BSMI, APAI AND TAQI POLYMORPHISMS













BBAATt 1 2 – 1
BBAAtt – 1 5 7
BBAaTT – – – 1
BBAaTt 1 – – 1
BbAATT – – – 1
BbAATt 2 6 3 1
BbAAtt – 4 – –
BbAaTT – 5 2 2
BbAaTt 16 8 7 10
BbaaTT – 4 – 1
bbAATT 1 – – –
bbAAtt – – – 1
bbAaTT 8 5 5 8
bbAaTt – – – 2
bbaaTT 6 5 3 4
TABLE 2
RELATIVE BSMI-APAI-TAQI HAPLOTYPE FREQUENCIES (%) IN CONTROL PATIENTS AND IN SUBGROUPS OF DISEASE-AFFECTED





DM (N=25) PV (N=40) DM-PV (N=35)
baT 0.980 37.1 (28.2–47.5) 39.1 (26–56) 37.5 (27–48.4) 51.2 (42.9–61.4)
BAt 0.989 32.9 (22–45.9) 39.5 (28–52) 26.1 (17.6–34.7) 29.7 (21.4–38.6)
bAT 0.922 13.2 (6.3–20.1) 16.4 (8–26) 14.9 (5.6–25) 17.1 (8.6–25.7)
BAT 0.781 5.8 (1.3–11.2) 3.6 (0–12) 8.1 (0–16.9) 1.4 (0–4.3)
bAt 0.762 5.3 (0–12.2) – 6.9 (1.6–15.4) –
BaT 0.776 4.5 (0–9.7) – 6.3 (1.5–13.2) –
Global haplotype effect** 0.544 0.976 0.064
and BsmI. According to the results of that study allele b
and haplotypes bT and bAT could encourage develop-
ment of diabetes mellitus Type I49. Malecki and associ-
ates performed case-control study, in which they ana-
lysed association between FokI, BsmI, ApaI and TaqI
polymorphisms of the VDR gene and tendency for devel-
opment of diabetes mellitus Type II in the population of
Poland. 308 patients suffering from diabetes mellitus
and 240 healthy control patients were included in the
study. Researches did not find any difference between al-
lele frequency neither in control patients nor in diabetic
patients. They found equal distribution of haplotypes
and their combinations in both studied patient groups,
whereupon VDR gene polymorphisms would not influ-
ence development of diabetes in Polish patients. Never-
theless, researchers suggested further study following
the same path but performed on a bigger patient sam-
ple50. Pani and associates performed a study that in-
cluded 152 German families. They analyzed 4 polymor-
phic restriction sites in the VDR gene (FokI, BsmI, ApaI
and TaqI) considered as potential causative agents for
development of diabetes mellitus Type I in the German
population. According to their finding, the restrictive site
FokI should not influence development of diabetes melli-
tus at all51. [krabi} and associates included in their study
134 patients suffering from diabetes mellitus Type I and
132 healthy control patients. The objective of their study
was either to determine or to deny association between
VDR gene polymorphisms and tendency for development
of diabetes mellitus Type I in the population of Dalmatia
in the Southern Croatia. The results of the study con-
firmed high association between BBAAtt genotype com-
bination and development of the diabetes mellitus Type
I. Also, authors of the study suggested further, extended
research52. The study showed that under presumption of
allele effective multiplicative model there are no signifi-
cant differences in distribution of genotype frequencies
of the BsmI, ApaI or TaqI polymorphisms between con-
trol patients and subgroup of diabetes patients. Accord-
ing to the co-dominant model, the most common geno-
types found in both control patients and diabetes patients
were Bb, Aa and TT. The analysis of allele frequencies of
the TaqI, ApaI and BsmI polymorphisms showed that
the most common alleles in diabetes patients are T, A and
b. Haplotype analysis performed in this study showed
that the haplotype Bat is the most common haplotype in
diabetes patients. The study examined VDR gene and its
polymorphisms also in psoriasis patients. Differences in
distribution of genotype frequencies of the BsmI, ApaI
and TaqI polymorphisms between control patients and
patients suffering from psoriasis vulgaris were not found.
In both groups the most common genotypes were Bb, Aa
and TT. Single most common alleles found in both con-
trol and psoriasis patients were T, A and b. Haplotype
analysis determined baT haplotype as the most common
one in psoriasis patients. Saeki and associates compared
VDR gene polymorphisms found in 115 patients suffer-
ing from psoriasis vulgaris and in 69 healthy control pa-
tients in the Japanese population. The results showed
higher prevalence of bb and TT genotypes in affected pa-
tients. Also, there was no significant difference in distri-
bution of genotype frequencies of the ApaI polymorphi-
sms in both examined patient groups. The study showed
that B and t alleles had lower prevalence in affected pa-
tients group, whereas equal frequency of allele A was
found in both examined groups. Taking into consider-
ation the obtained results, in the conclusion the authors
confirmed possible role of the VDR gene allele variants in
predisposition to psoriasis vulgaris53. Park and associates
studied the Korean population (104 psoriasis patients
and 104 control patients were including). Opposite to the
previously mentioned studies, results of their study sho-
wed prevalence of allele A in patients suffering from pso-
riasis vulgaris compared to the control group patients. At
the same time, there was a significant correlation be-
tween homozygous AA and development of psoriasis
vulgaris at the early age of patients54. In her study,
Ru~evi} examined possible association between psoriasis
vulgaris and VDR gene polymorphisms for ApaI, BsmI
and TaqI. None of analyzed polymorphisms individually,
also after the adjustment according to the age of pa-
tients, did not show differential age, gender or phenotype
specific effects on the risk of developing psoriasis vul-
garis. Also, in general population there was no associa-
tion between any analyzed polymorphism individually
and a measurable risk for development of psoriasis vul-
garis, psoriasis Type I or Type II. However, the allele Bt
is associated with individual protective effect in psoriasis
vulgaris Type I, but not in Type II. Ru~evi} concluded
that VDR polymorphism can be associated with psoriasis
but with significant race differences55.
In this study we examined VDR gene and its poly-
morphisms in patients affected with both diseases (psori-
asis vulgaris and diabetes mellitus). There are no studies
in the available literature about other researchers exam-
ining more detailed the VDR gene as potential causative
agent for development of both psoriasis vulgaris and dia-
betes mellitus in one patient. Thereby it makes it diffi-
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TABLE 3
HARDY-WEINBERG EQUILIBRIUM TEST RESULTS
RFLP
(NCBI dbSNP ID)
Control patients (N=40) DM (N=25) PV (N=40) DM+PV (N=35) Combined sample (N=140)
Exact P* Exact P* Exact P* Exact P* Exact P*
BsmI (rs1544410) 0.193 1 0.021 0.444 0.478
ApaI (rs7975232) 0.213 0.682 0.537 0.046 0.092
TaqI (rs731236) 0.19 0.423 0.718 0.132 0.462
cult to discuss or compare possibly same or different re-
sults obtained by other authors. When comparing control
patients and a subgroup of patients suffering from both
psoriasis vulgaris and diabetes mellitus (PV+DM), we
did not find any difference in distribution of genotype
frequencies of the BsmI, ApaI polymorphisms, with ex-
ception of TaqI polymorphisms. The most common geno-
types in both studied groups are Bb and Aa. Tt genotype
is the most common genotype in patients suffering from
both PV and DM and TT is the most common in control
patients. T, a and b alleles are the most common in con-
trol patients and T, a and b in PV+DM patients. The re-
sults of the Haplotype analysis method showed that
haplotype baT is the most common in both PV+DM pa-
tients and control patients group. Further to the above
results, in all analyzed patient groups we detected 3 out
of 9 haploid alleles with frequency 10%. In accordance
with other published results56 also this study showed
that the most common VDR 3’-RFLP haplotypes are
tri-component baT, Bat and bAT. For more precise assess-
ment of population haplotype frequencies we need signif-
icantly bigger patients sample.
To conclude: within restrictions determined by the
size and characteristics of the sample, by the limited sta-
tistical power and multiplicity of tests, by application of
empiric statistics that is maintaining statistical testing
validity in set conditions, in studied population there is
no association between analyzed polymorphisms individ-
ually and risk of psoriasis vulgaris, risk of diabetes me-
llitus or combined phenotype. However, taking into con-
sideration limited statistical power, one can not exclude
with certainty a significant residual effect of individual
polymorphisms, which was not possible to determine in a
given sample. This conclusion should be basis for further
studies with bigger samples.
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POLIMORFIZMI VDR GENA U OBOLJELIH OD VULGARNE PSORIJAZE I [E]ERNE BOLESTI S
PODRU^JA ISTO^NE HRVATSKE
S A @ E T A K
Cilj ovoga rada bio je istra`iti mogu}u udru`enost polimorfizama u genu za vitamin D receptor (VDR gen) sa sklo-
no{}u obolijevanju od vulgarne psorijaze i {e}erne bolesti u populaciji Slavonije, odnosno Isto~ne Hrvatske. S obzirom
na to polimorfizmi u duljini restrikcijskih odsje~aka (ApaI, BsmI i TaqI) u genu za receptor vitamina D su analizirani u
bolesnika oboljelih samo od vulgarne psorijaze, u bolesnika oboljelih samo od {e}erne bolesti i u bolesnika oboljelih
istovremeno od vulgarne psorijaze i {e}erne bolesti. U svih tipiziranih kontrolnih ispitanika na|ena su ~etiri naj~e{}e
zastupljena genotipa: trostruki heterozigoti BbAaTt (kod 29,3% ispitanika), bbAaTT (kod 18,6% ispitanika), bbaaTT
(kod 12,9% ispitanika) i BbAATt genotip (kod 8,6% ispitanika). U ovoj studiji tri naj~e{}a VDR 3’-RFLP haplotipa su
bili trokomponentni baT, BAt i bAT haplotip. Rezultati Hardy-Weinberg-ovog ekvilibrija uputili su na disekvilibrij ge-
notipskih frekvencija BsmI polimorfizma u skupini oboljelih od vulgarne psorijaze i ApaI polimorfizma u oboljelih od
obje bolesti. Prema istom statisti~kom testu ispunjeni su uvjeti u svim skupinama ispitanika za genotipske frekvencije
TaqI polimorfizma. U distribuciji genotipskih frekvencija BsmI, ApaI ili TaqI polimorfizama izme|u kontrolnih is-
pitanika i bilo koje podskupine nije bilo zna~ajnih razlika. Niti jedan analizirani polimorfizam pojedina~no nije bio
udru`en s rizikom obolijevanja od vulgarne psorijaze, {e}erne bolesti ili kombiniranog fenotipa u ispitivanoj populaciji.
